Drug Trial Radar · NCT00856206
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,315
Actual
Start
Mar 2009
Primary completion
Jan 2011
Study completion Jan 2011
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 5, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.
Conditions
- Gout
Interventions
RilonaceptBiological
Rilonacept 160 mg subcutaneous injection once a week
PlaceboOther
Placebo subcutaneous injection once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 20
Locations
124 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Alabaster, Alabama
Site not named
Mesa, Arizona
Site not named
Burbank, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Upland, California
Site not named
Brooksville, Florida
Site not named
Clearwater, Florida
Site not named
DeBary, Florida
Site not named
DeLand, Florida
Site not named
Jacksonville, Florida
Site not named
Naples, Florida
Site not named
Palm Harbor, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Canton, Georgia
Site not named
Decatur, Georgia
Site not named
Sandy Springs, Georgia
Site not named
Stockbridge, Georgia
Site not named
Boise, Idaho
Site not named
Brownsburg, Indiana
Site not named
Evansville, Indiana
Site not named
Greenfield, Indiana
Site not named
Bowling Green, Kentucky
Site not named
Elizabethtown, Kentucky
Site not named
Lexington, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Springfield, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Bingham Farms, Michigan
Site not named
Brooklyn Center, Minnesota
Site not named
Richmond Heights, Missouri
Site not named
St Louis, Missouri
Site not named
Billings, Montana
Site not named
Kalispell, Montana
Site not named
Lincoln, Nebraska
Site not named
Elizabeth, New Jersey
Site not named
Albuquerque, New Mexico
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.